Company profile

AB Science

AB · Euronext Paris · France

Public Market Listing

ABEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for AB Science are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Masitinib
Phase 3
c-Kit/Lyn/Fyn tyrosine kinases (mast cell/microglia) · c-Kit (CD117); also PDGFR, Lck, FAK, FGFR3, CSF1R · KIT (c-Kit), also PDGFR and Lyn/Fyn kinasesSmall molecule
Alzheimer's DiseaseAsthma
AB8939
Phase 2
Tubulin
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.